Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind phase II trial of NY-ESO-1 ISCOMATRIX versus ISCOMATRIX adjuvant alone in resected malignant melanoma
2004-005118-35Phase 2Completed
- Sponsor
- Ludwig Cancer Research
- Start
- Mar 2005
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NY-ESO-1 ISCOMATRIX vaccine in melanoma (2 arms), sponsored by Ludwig Cancer Research. Primary endpoint: Relapse-free survival at 18 months. Started Mar 2005; status: completed.
02
Drugs
NY-ESO-1 ISCOMATRIX vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on 2004-005118-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005118-35.